• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

November 15, 2012 - Exelixis

http://www.exelixis.com/

Dana T. Aftab, PhD - SVP, Translational Research
Arthur DeCillis, MD - VP, Clinical Development and Medical Affairs

Presentation on:

  • Cabozantanib (XL-184)


October 18, 2012 - Pfizer

http://www.pfizer.com/home/

David A. Roth, MD - VP, Early Drug Development
James G. Christensen, PhD - Sr. Director, Precision Medicine
Ashwin Gollerkeri, MD - Executive Director, Oncology Clinical Development
Diana H. Giorgio, PhD - Director, US Medical Affairs

Presentation on: 

  • Pfizer Oncology Pipeline


September 7, 2012 - Genentech

http://www.gene.com/gene/index.jsp

Stuart Lutzker, MD - PhD Vice-President Exploratory Clinical Development
Chris Bowden, MD - Vice President BioOncology, Clinical Development
Terry Rugg, MD - Vice-President, US Medical Affairs
Jennifer Low, MD - Group Medical Director, BioOncology
Bernard Fine, MD - Associate Group Medical Director
Dan Chen, MD, PhD - Associate Group Medical Director
Mika Derynck, MD - Associate Group Medical Director

Presentation on:

  • Armed Abs (ADCs)
  • Immunotherapy
  • MetMab
  • PI3K and downstream effectors


February 9, 2012 - AVEO Pharmaceuticals

www.aveopharma.com

Eileen Rich - Senior Medical Science Liaison
Murray Robinson - Senior Vice President of Translational Medicine
May Han - Program Director of Preclinical Development
Anna Berkenblit - Vice President & Head of Clinical Research
Pritesh Shah - Senior Director, New Product Marketing
James Stec - Director, Medical Affairs
Shefali Agarwal - Medical Director
Brooke Esteves - Director, Clinical Research

Presentation on:

  • AVEO Pipeline


April 19, 2012 - ARIAD Pharmaceuticals

http://www.ariad.com

Frank Haluska, MD, PhD - CMO, SVP
Tim Clackson, PhD - President, R&D
Bill Shakespeare, PhD - Drug Discovery
Jing Marantz MD - VP Med Affairs
Marty Duvall - SVP Global Commercial Operations

Presentation on:

  • Ponatinib (pan BCR-ABL inhibitor in studies for CML, Ph+AML, others)
  • AP26113 (dual EGFR-ALK inhibitor)


May 17, 2012 - Sanofi

http://www.sanofi.us

Tal Zaks - Head of Development
Rob Sands - Project Head-Jevtana
Pam Cohen - Project Head-JAK-2
Jo Lager - Project Head-PI3K inhibitor
Don Bergstrom - Head of Translational Medicine
Varavani Dwarki - Oncology Alliance Management
Kathryn Corzo - Project Head-Anti CD38

Presentation on: 

  • Sanofi pipeline